Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

Blood

Volumn 117, Issue 20, 2011, Pages 5514-5522

  Waters, Emily K ^a   Genga, Ryan M ^a   Schwartz, Michael C ^a   Nelson, Jennifer A ^a   Schaub, Robert G ^a   Olson, Karen A ^a   Kurz, Jeffrey C ^a   McGinness, Kathleen E ^a  

^a Archemix Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; ARC 17480; ARC 19499; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; DNA; HEMOSTATIC AGENT; MACROGOL DERIVATIVE; OLIGONUCLEOTIDE; PROCOAGULANT; PROTEIN INHIBITOR; SODIUM CHLORIDE; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BIOLOGICAL PHENOMENA AND FUNCTIONS; BLEEDING TIME; BLOOD CLOTTING; BOLUS INJECTION; CONTROLLED STUDY; CYNOMOLGUS MONKEY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; ENZYME ACTIVITY; HAPLORHINI; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; THROMBIN GENERATION; THROMBOELASTOGRAPHY;

EID: 79956299608     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-311936     Document Type: Article

References (45)

1. Srivastava A; WFH Treatment Guidelines Working Group. Guidelines for the management of hemophilia. Montreal, QC: World Federation of Hemophilia; 2005.
2. Pipe S. Visions in haemophilia care. Thromb Res. 2009;124(suppl 2):S2-S5.
3. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28(2):233-242. (Pubitemid 351161194)
4. Maroney SA, Haberichter SL, Friese P, et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood. 2007;109(5):1931-1937. (Pubitemid 46348189)
5. Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost. 1991;66(4):464-467.
6. Welsch DJ, Novotny WF, Wun TC. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. Thromb Res. 1991;64(2):213-222.
7. Erhardtsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis. 1995;6(5):388-394.
8. Liu T, Scallan CD, Broze GJ Jr, Patarroyo-White S, Pierce GF, Johnson KW. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost. 2006;95(1):68-76.
9. Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood. 2008;111(2):672-679.
10. Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry. 1995;34(43):13988-13993.
11. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010;50:237-257.
12. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249(4968):505-510.
13. Burmeister PE, Lewis SD, Silva RF, et al. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem Biol. 2005;12(1):25-33. (Pubitemid 40118323)
14. Wong I, Lohman TM. A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc Natl Acad Sci U S A. 1993;90(12):5428-5432. (Pubitemid 23176173)
15. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993;268(36):26950-26955.
16. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15. (Pubitemid 37449290)
17. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989;338(6215):518-520. (Pubitemid 19107996)
18. Petersen LC, Bjorn SE, Olsen OH, Nordfang O, Norris F, Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem. 1996;235(1-2):310-316. (Pubitemid 26048630)
19. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 1998;273(8):4378-4386. (Pubitemid 28103174)
20. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA. 2006;103(9):3106-3111. (Pubitemid 43346432)
21. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32(5-6):249-253. (Pubitemid 37490547)
22. Dargaud Y, Negrier C. Thrombin generation testing in haemophilia comprehensive care centres. Haemophilia. 2010;16(2):223-230.
23. Salvagno GL, Astermark J, Lippi G, et al. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia? Haemophilia. 2009;15(1):290-296.
24. Dargaud Y, Beguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005;93(3):475-480. (Pubitemid 40392535)
25. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.
26. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005;27(2):81-90. (Pubitemid 40515992)
27. Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost. 2004;2(1):102-110. (Pubitemid 40185626)
28. Othman M, Powell S, Chirinian Y, Hegadorn C, Hopman W, Lillicrap D. Thromboelastography reflects global hemostatic variation among severe haemophilia A dogs at rest and following acute exercise. Haemophilia. 2009;15(5):1126-1134.
29. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006;12(6):598-604. (Pubitemid 44697530)
30. Chitlur M, Warrier I, Rajpurkar M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol. 2008;142(2):250-256. (Pubitemid 351987306)
31. Lozier JN, Dutra A, Pak E, et al. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proc Natl Acad Sci U S A. 2002;99(20):12991-12996.
32. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
33. Tranholm M, Kristensen K, KristensenAT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102(10):3615-3620. (Pubitemid 37409379)
34. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90(10):3962-3966. (Pubitemid 27484049)
35. Tomokiyo K, Nakatomi Y, Araki T, et al. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Vox Sang. 2003;85(4):290-299. (Pubitemid 37522603)
36. Healy JM, Lewis SD, Kurz M, et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res. 2004;21(12):2234-2246. (Pubitemid 40568437)
37. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl. 1999;732(1):203-212. (Pubitemid 29421761)
38. Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost. 2003;1(7):1349-1355.
39. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9(4):464-520. (Pubitemid 36874393)
40. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537-550.
41. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7(4):392-396. (Pubitemid 32677658)
42. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia. 2004;10(suppl 4):97-104.
43. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55(6):638-648. (Pubitemid 24212264)
44. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost. 2009;7(4):651-657.
45. Christiansen ML, Balling KW, Persson E, et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia. 2010;16(6):878-887.